Logo-apb
Adv Pharm Bull. 2023;13(1): 88-95.
doi: 10.34172/apb.2023.007
PMID: 36721805
PMCID: PMC9871265
  Abstract View: 881
  PDF Download: 520
  Full Text View: 111

Mini Review

Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment

Luísa Biscaglia Miquelotti 1 ORCID logo, Marcel Henrique Marcondes Sari 2 ORCID logo, Luana Mota Ferreira 1,3* ORCID logo

1 Departamento de Farmácia Industrial, Curso de Farmácia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, Brazil.
2 Curso de Farmácia, Instituto de Desenvolvimento Educacional de Passo Fundo - UNIDEAU, Passo Fundo, Brazil.
3 Programa de Pós-graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, Brazil.
*Corresponding Author: *Corresponding Author: Luana Mota Ferreira, Tel: (55) 9 96385657, Email: , Email: luana.ferreira@ufsm.br

Abstract

Purpose: Cancer is a global public health problem that affects millions of people every year and the immunotherapy has been a promising alternative for its treatment. The aim of this study was to gather data concerning the efficacy and safety of immunotherapy in the treatment of non-small cell lung cancer (NSCLC), emphasizing pembrolizumb, a humanized antibody. This study also reports the role of immunotherapy in cancer treatments, contemplating the anti-CTLA4, anti-PD-L1 and anti PD-1 action in lymphocyte T cells.

Methods: A bibliographic review was performed using Pubmed, SCIELO and SCOPUS databases, screening the scientific studies published within the last 5 years.

Results: Seven clinical trials were selected to discuss the benefits of pembrolizumab as NSCLC therapy in untreated and previously treated patients, considering or not the tumor proportion score (TPS). It was found that NSCLC occurs with great frequency in Brazil and worldwide, presenting a poor prognosis due to its late diagnosis in most cases. Immunotherapy is a promising treatment strategy for NSCLC because its benefits overcome its risks compared to other therapies. Besides, the studies evidenced the efficiency of pembrolizumab as monotherapy or in association whit chemotherapy, in the first or second line of treatment and, additionally, patient’s whit TPS ≥ 50% seem to have a greater benefit from the treatment.

Conclusion: The data collected herein showed that pembrolizumab is a very promising, effective, and safe treatment option against NSCLC. Lastly, it is important to highlight the relevance of review’s studies, since they are easy-to-read materials, collecting relevant information on a subject.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 882

Your browser does not support the canvas element.


PDF Download: 520

Your browser does not support the canvas element.


Full Text View: 111

Your browser does not support the canvas element.

Submitted: 18 Jul 2021
Revision: 20 Aug 2021
Accepted: 28 Sep 2021
ePublished: 10 Oct 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)